Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)

Completed · Phase 4

Conditions studied: Nontuberculous Mycobacteria, Mycobacterium Avium Complex

In brief

Use of oral clarithromycin for treatment of chronic lung disease due to Mycobacterium avium-intracellulare and other non-tuberculous Mycobacteria

Key facts

Study ID

NCT00600769

Run by

The University of Texas Health Science Center at Tyler

People needed

210

Starts

1991-01-01

Expected to finish

2017-05-18

Last updated by the study team

2017-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet American Thoracic Society criteria for nontuberculous lung disease: two or more AFB smear positive, culture positive sputums or bronchoscopic samples and/or two or more AFB smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal CXR consistent with M. avium lung disease; absence of other potential lung pathogens (except for the coexistence of M. abscessus)
• Age 18 years and older

You may not qualify if…

• History of macrolide allergy
• Must not receive the antihistamines terfenadine (Seldane) or astemizole (Hismanal) while on clarithromycin
• Children less than 18 years of age
• If a menstruating female, not pregnant and on adequate birth control

Where it is running

• The University of Texas Health Science Center at Tyler — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.